New hope for frail AML patients: less toxic drug combo shows promise

This study tests a new drug combination using selinexor with fewer or no harsh chemo drugs for adults newly diagnosed with acute myeloid leukemia (AML) who are too frail for standard intensive chemo. The goal is to quickly reduce leukemia cells while causing fewer side effects. About 71 participants will be followed to see if this approach improves survival and allows doctors to adjust treatment early based on how the patient responds.